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LETTER TO THE EDITOR
Endoxifen: A new hope for Bipolar Disorder
Muneeba Amin, Alviya Shafique, Muhammad Yusuf Hafiz
Madam, Bipolar Disorder (BD), originally called manic
depressive illness, is one of the most challenging and
disabling psychiatric disorders to manage with an
estimated life time prevalence of 1.02%.1 One of the
challenges is limitations in our understanding of the
pathophysiology of the disorder which ultimately will lead
to better treatment options. Despite available treatment
options, literature reports breakthrough episodes in treated
groups ranging from 40% to 60%.2 This makes it even more
crucial to gain more insight into the pathophysiology.
Advances in molecular neuropsychiatry have reported that
bipolar disorder is associated with overactive protein C
kinase intracellular signalling.3 Reportedly, lithium and
valproate are protein C kinase inhibitors. Research has
shown promise in eﬀectiveness of Endoxifen. A
multicentre, double-blind, active-controlled study was
conducted using Endoxifen compared with Divalproex, the
current standard treatment, in patients with BD. This new
protein kinase C inhibitor has shown eﬀectiveness in the
treatment of acute mania and mixed mania.4 One of the
many advantages include similar eﬃcacy as Divalproax
without inducing thrombocytopenia and reportedly no
need for drug monitoring due to wide therapeutic index is
one of the reasons which results in decreased compliance.
Additionally, it crosses the blood-brain barrier independent
of CYP-2D6 metabolism.4 With regards to disadvantages,
cost eﬀectiveness is a major hurdle. These new insights into
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pathophysiology and treatment options are crucial as till
date BD remains one the most disabling mental health
disorder aﬀecting every aspect of life; individual, social,
economic, global. BD is the fifth leading cause among
psychiatric disorders of lost years of work.5 It is therefore
imperative that a new treatment is established and further
research is warranted in regards to Endoxifen for better
understanding to develop safe treatment, not only for
management but possible cure.
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